Anaconda Biomed closes a $56 million financing round to advance its thrombectomy catheter program. The medical technology company is developing novel thrombectomy catheters based on its core funnel catheter platform, and says the proceeds will support completion of the ongoing ATHENA pivotal IDE study, a prospective, randomized trial of 327 subjects evaluating the ANA Funnel Catheter.
Anaconda Biomed closes a $56 million financing round to support its ANA funnel catheter trial. The proceeds will support completion of the 327-patient ATHENA pivotal investigational device exemption study of the ANA funnel catheter. Anaconda Biomed develops a portfolio of thrombectomy catheters based on its core funnel catheter technology platform.
Anaconda Biomed receives CE Mark certification for its ANA5 Funnel Catheter, authorizing commercial distribution across Europe. Designed for mechanical thrombectomy in ischemic stroke, the catheter uses funnel-shaped geometry intended to maximize clot capture and improve first-pass recanalization rates.
Anaconda Biomed reports that results from its ANAIS Study of the ANA funnel catheter are published in the American Journal of Neuroradiology. The study evaluates the catheter’s safety and performance in endovascular treatment of large vessel occlusion acute ischemic stroke, with data showing high reperfusion and first-pass success rates and a strong safety profile.
Anaconda Biomed, SL announces publication of results from ANAIS, a study evaluating the safety and performance of its ANA funnel catheter in endovascular treatment of large vessel occlusion acute ischemic stroke. The company says the catheter is designed for use with stent retrievers to arrest blood flow and reduce the risk of clot fragmentation during mechanical thrombectomy.
Anaconda Biomed appoints medical technology executive Trent Reutiman as its new CEO. Based in California’s San Francisco Bay Area, Reutiman will establish a U.S. footprint for the company as it pursues regulatory approval for ANA5, its Advanced Neurovascular Access catheter technology designed to improve neurovascular interventions.
Anaconda enrolls the first U.S. patient in ATHENA, a clinical trial evaluating its ANA Funnel Catheter for ischemic stroke treatment. The global, randomized pivotal study evaluates the device’s safety and effectiveness in 327 patients. Used during stent retriever-based thrombectomy, the catheter restricts blood flow during clot retrieval to enable simultaneous aspiration and reduce clot fragmentation in patients with large-vessel occlusion acute ischemic stroke.
Anaconda Biomed S.L. receives a European patent for a device and thrombectomy apparatus to extract thrombus from a blood vessel. The European patent, EP3866708 B1, was published on September 27, 2023; the company also received US patent 11,771,446 B2 on October 3, 2023, for a method to improve the efficacy of removing cerebral vascular thrombi.
Anaconda Biomed is set to receive up to €10 million in venture debt from the European Investment Bank. The funding supports development of its second-generation catheter for treating acute ischemic stroke (AIS), in what the article identifies as Spain’s second venture debt operation backed by the European Guarantee Fund.